Cobalt-Related Exposures

The Report on Carcinogens includes two separate listings (i.e., profiles) for cobalt-related exposures: Cobalt and Cobalt Compounds That Release Cobalt Ions In Vivo and Cobalt-Tungsten Carbide: Powders and Hard Metals. Cobalt and cobalt compounds as a class are listed for the first time in the Fourteenth Report on Carcinogens, and this listing includes and supersedes the listing for cobalt sulfate, which first appeared in the Eleventh Report on Carcinogens. Cobalt–tungsten carbide was first listed in the Twelfth Report on Carcinogens. The profiles for these listings follow this introduction.

Cobalt and Cobalt Compounds That Release Cobalt Ions In Vivo

CAS No. 7440-48-4 (Cobalt metal)

No separate CAS No. assigned for cobalt compounds as a class

Reasonably anticipated to be human carcinogens

Introduction

This listing of the class of cobalt and cobalt compounds that release cobalt ions in vivo (as defined below) supersedes the previous listing of cobalt sulfate in the Report on Carcinogens. The compound cobalt sulfate was first listed in the Eleventh Report on Carcinogens in 2004 as reasonably anticipated to be a human carcinogen based on sufficient evidence of carcinogenicity in experimental animals.

Carcinogenicity

Cobalt and cobalt compounds that release cobalt ions in vivo are reasonably anticipated to be human carcinogens based on sufficient evidence of carcinogenicity from studies in experimental animals and supporting data from studies on mechanisms of carcinogenesis. Mechanistic data indicate that the release of cobalt ions in vivo is a key event for cobalt-induced carcinogenicity. The available data show that cobalt metal and cobalt compounds that release cobalt ions in vivo (regardless of their solubility in water) act via similar modes of action to cause similar types of effects, including cell death, DNA damage, and cancer, and that the cobalt ion is largely responsible for the toxicity and carcinogenicity (NTP 1998, 2014, IARC 2006).

Both water-soluble cobalt compounds and poorly water-soluble cobalt particles are included in this class, as both types of cobalt species can release cobalt ions in vivo, although they differ in the mechanisms by which the cobalt ions enter cells. Vitamin B₁₂, which is an essential cobalt-containing nutrient, does not meet the criteria for this listing, because the vitamin does not release cobalt ions, but passes through the body intact while bound to specific carrier proteins (Neale 1990). It is not possible to determine the quantitative carcinogenic risk from cobalt ions released from surgical implants because of limitations in the available cancer studies of cobalt alloy implants in experimental animals and of patients with cobalt-containing surgical implants.

Mechanisms of Carcinogenesis and Other Relevant Data

The key events related to toxicity and carcinogenicity are thought to include cellular uptake of cobalt, intracellular release of cobalt ions from particles, and immediate and downstream biological responses related to the proposed modes of action. The first step in the carcinogenicity or toxicity process is the release of cobalt ions in vivo. Water-soluble cobalt compounds release cobalt ions into fluids outside the cell, and the ions enter the cell through ion channels within the cell membrane. In contrast, poorly soluble particulate cobalt compounds are taken up by specific organelles (lysosomes) in the cell via a process called endocytosis; cobalt is then solubilized in the acidic environment in the lysosomes, and the ions are released inside the cell. Evidence for cellular uptake of the different forms of cobalt is provided by studies evaluating their solubility in biological fluids in vitro (e.g., in gastric and lysosomal fluids) (see Properties) and in vitro studies measuring levels of cobalt ions within cells (Peters et al. 2007, Ortega et al. 2014, Sabbioni et al. 1994, Smith et al. 2014).

Although the mechanism(s) of action for cobalt-induced carcinogenic effects are not completely understood, several key events have been identified that are related to biologically plausible modes of action and are applicable to all cobalt forms that release cobalt ions in vivo. These events include inhibition of DNA repair, genotoxicity, generation of reactive oxygen species (ROS) resulting in oxidative damage, and stabilization of hypoxia-inducible factor 1α (HIF-1α), a protein that increases the expression of genes that promote survival of cells when they receive less oxygen. The proposed modes of action are summarized in the diagram below.

[Diagram of mechanistic events in cobalt carcinogenicity]

Adapted from De Boeck et al. (2003) and Beyermann and Hartwig (2008).
Cobalt is considered to be a clastogen, because in in vitro assays in mammalian cells, it primarily causes chromosome damage and DNA strand breaks. Only a few genotoxicity studies in experimental animals were available, but the results were generally consistent with those of in vitro studies. Two potential mechanisms for genotoxicity include (1) direct induction of oxidative damage to DNA by cobalt(II) ions and (2) an indirect effect through inhibition of DNA repair (Smith et al. 2014, Lison 2015).

Cobalt is one of a group of metals (transition metals, like iron and nickel) that promote oxidation and reduction (redox) reactions through transfer of electrons. In vitro studies have shown that cobalt particles and ions can induce ROS in mammalian cells, with cobalt metal and cobalt oxide particles having a greater effect than ions. It has been proposed that ROS can play a role in the tumordevelopment process at several stages, including initiating the process by inducing mutations and promoting proliferation of these mutated cells by deregulating controls on cell growth, leading to tumors. Studies in rats have shown that cobalt causes oxidative stress and oxidative DNA damage in several tissues, including kidney, liver, and lung (Kasprowszc et al. 1994), which supports this proposed pathway for cobalt-induced carcinogenicity. Also, a higher frequency of a specific mutation in the K-ras oncogene, a gene with the potential to cause cancer, was found in cobalt-induced lung tumors in mice and rats than in spontaneous lung tumors (NTP 1998, 2014, IARC 2006). This mutation involves substitution of one nucleotide for another in a G to T transversion, which is a mutation commonly associated with oxidative DNA damage. In addition, cobalt-induced oxidative stress (via the production of ROS) can activate genes and proteins (specifically, the transcription factors NF-κB, p53, and Nrf2) that in turn regulate the expression of many genes that play a role in carcinogenicity, such as those involved in inflammation and control of the cell cycle (Valko et al. 2005, 2006, Beyersmann and Hartwig 2008, Shukla et al. 2012, Davidson et al. 2015, PubChem 2015).

Finally, a well-established biological effect of cobalt is to mimic oxygen deficiency in cells by stabilizing HIF-1α (Maxwell and Salnikow 2004, Greim et al. 2009, Saini et al. 2010a,b, Galán-Cobo et al. 2013, Gao et al. 2013, Nyga et al. 2015). HIF-1α plays a central role in regulating more than 100 hypoxia-responsive genes and is a major regulator of the adaptation of cancer cells to oxygen deficiency. HIF-1α overexpression has been linked to cancer initiation and progression and is a common characteristic of many human cancers (Paul et al. 2004, Galanis et al. 2008, 2009, Cheng et al. 2013).

Although most of the toxicological effects of cobalt are attributed to the cobalt ion, direct toxic effects of cobalt particles also contribute, as evidenced by the greater toxicity of cobalt metal than of cobalt sulfate in National Toxicology Program (NTP) rodent bioassays (NTP 1998, 2014, Behl et al. 2015). Differences in the relative toxicity reported for cobalt particles and ions may be partially explained by differences in the mechanisms by which cobalt enters the cell and in the subsequent accumulation and distribution of cobalt within the cell, as well as a synergistic effect between the particles and metal on ROS production (Peters et al. 2007, Sabbioni et al. 2014, Smith et al. 2014).

**Cancer Studies in Experimental Animals**

Exposure of experimental animals to cobalt metal or cobalt compounds caused tumors in two rodent species, at several different tissue sites, and by several different routes of exposure. This conclusion is based on studies in rats and mice exposed to cobalt metal (five studies), water-soluble cobalt compounds (two studies with cobalt sulfate and one study with cobalt chloride), and poorly water-soluble cobalt compounds (four studies with cobalt oxide). Studies of cobalt alloys and radioactive cobalt in experimental animals were not considered to be informative, because of potential confounding by other carcinogens.

Inhalation exposure of rats and mice to cobalt metal (NTP 2014) or cobalt sulfate (NTP 1998) or intratracheal instillation of cobalt oxide in rats (Steinhoff and Mohr 1991) caused lung tumors (alveolar/bronchial adenoma and carcinoma). In addition, inhalation exposure of rats to cobalt metal caused squamous-cell tumors of the lung (primarily cystic keratinizing epithelioma) in females and possibly in males.

In inhalation studies of cobalt metal in rats (NTP 2014), tumors were also induced at sites distant from the lung, including tumors of the pancreas (islet-cell adenoma or carcinoma combined) in males and of the hematopoietic system (mononuclear-cell leukemia) in females, indicating a systemic effect. Increased incidences of kidney tumors (adenoma or carcinoma combined) in male rats and pancreas (carcinoma) in female rats may have been related to cobalt metal inhalation; however, the findings were not conclusive. Inhalation exposure to cobalt metal (NTP 2014) or cobalt sulfate (NTP 1998) induced adrenal-gland tumors (benign and malignant pheochromocytoma), which could have been caused by direct or indirect mechanisms.

In rats, local injection of cobalt at various anatomic locations caused tumors at the injection sites. Although these studies were less robust than the inhalation studies, and sarcomas are common in rats following injection of a variety of compounds, the consistency of the tumor types and findings across different cobalt forms provides supporting evidence for the carcinogenicity of cobalt. Intraperitoneal or intramuscular injection of the poorly water-soluble compound cobalt oxide caused histiocytoma or sarcoma at the injection site (Gilman and Ruckerbauer 1962, Steinhoff and Mohr 1991), and subcutaneous injection of the water-soluble compound cobalt chloride caused fibrosarcoma (Shabaan et al. 1977). Intramuscular or intrathoracic injection of cobalt metal (Heath 1956, Heath and Daniel 1962) or nanoparticles (Hansen et al. 2006) caused various types of sarcoma (primarily rhabdomyofibrosarcoma, rhabdomyosarcoma, or fibrosarcoma). In the study of nanoparticles, no tumors were observed after implantation of substances (e.g., titanium dioxide and silicon dioxide) with the same physical characteristics (i.e., surface-to-volume ratio) as cobalt, suggesting that the tumors were due to carcinogenic properties of cobalt and not just to a reaction to any physical implant.

A few studies in rodents (Gilman and Ruckerbauer 1962, Jasmin and Riopelle 1976, Wehner et al. 1977) found no tumors at certain tissue sites following exposure to the same forms of cobalt that caused tumors in other studies; however, these studies generally lacked sensitivity to detect an effect, because of the use of a less sensitive animal model, shorter study duration, or lower exposure levels.

**Cancer Studies in Humans**

The data available from studies in humans are inadequate to evaluate the relationship between human cancer and exposure specifically to cobalt and cobalt compounds that release cobalt ions in vivo. The data relevant to the evaluation were from studies primarily evaluating lung cancer in five independent cohorts of workers in different types of industries and two population-based case-control studies of esophageal cancer and other cancers of the respiratory and upper digestive (aerodigestive) tract, one in Ireland (O’Rorke et al. 2012) and the other in the state of Washington (Rogers et al. 1993). Studies of cobalt alloys in humans (primarily joint implants) were not considered to be informative, because they were not specific to cobalt exposure, and the extent of any cobalt exposure was unknown.

Although increased risks of lung cancer were found in most of the cohort studies, it is unclear that the excess risks were due to exposure specifically to cobalt, because of potential confounding from
exposures to known lung carcinogens or other study limitations. In the cohort studies, hard-metal (Moulin et al. 1998, Wild et al. 2000) and nickel-refinery workers (Grimsrud et al. 2005) were also exposed to known lung carcinogens. The findings of an increased risk of lung cancer among porcelain painters exposed to cobalt was complicated by a somewhat similar increase in risk among female pottery workers who were not thought to be exposed to cobalt (Tuchsen et al. 1996). In studies of a cohort of cobalt production workers, the excess risk found in the first report of this cohort (Mur et al. 1987) was no longer present in an update of the cohort (Moulin et al. 1993). No association between cobalt exposure and lung cancer was found in a study of stainless- and alloyed-steel workers in France (Moulin et al. 2000). Most of the studies had limited sensitivity to detect a true risk, because of small numbers of lung-cancer cases among exposed workers, crude methods of exposure assessment, or potential healthy-worker-related effects (due to the fact that workers are healthier on average than the general population).

Increased risks of esophageal cancer were suggested in two case-control studies; however, it is unclear whether cobalt exposure contributed to the cancer excess. In both studies, cobalt exposure was assessed from a single sample of toenail clippings taken at or several months after diagnosis of esophageal cancer. Measurements of cobalt in toenails reflect an integrated exposure that occurred 12 to 18 months before clipping, raising the question of whether levels found in toenails close to or, in many cases, after cancer diagnosis reflected the relevant period of exposure for long-latency cancer.

### Properties

As a class, cobalt and cobalt compounds that release cobalt ions in vivo are related largely by their chemical properties, specifically bioavailability. (The different valence states of cobalt are described below, under Chemical Characteristics.)

#### Bioavailability

The carcinogenic and toxic effects of cobalt and cobalt compounds begin with the release of cobalt ions in vivo. The bioavailability of a metal species can be predicted by its solubility in biological fluids, such as synthetic equivalents of gastric and intestinal fluids (for ingestion exposure) or lung (alveolar, interstitial, and lysosomal) fluids (for inhalation exposure), and by studies in cultured cells. Results from studies testing solubility in synthetic biological fluids are shown in the table below, along with other chemical and physical properties of cobalt metal and these cobalt compounds. These studies demonstrated that cobalt metal and both water-soluble and poorly water-soluble cobalt compounds can dissolve and release cobalt ions in some biological fluids (Brock and Stopford 2003, Stopford et al. 2003, Cobalt Development Institute personal communication 21 Jul and 19 Oct 2015), suggesting that they will release ions in vivo.

Very low values (≤ 2%) for bioaccessibility have been reported for the sulfide and mixed (II,III) oxide (CoO$_2$), and intermediate values (14% to 55%) for stearate and oxalate under the same test conditions. However, other, more informative tests with more physiologically relevant test conditions (e.g., two-week studies with 0.3-µm particles in culture medium in the presence of alveolar macrophages) have reported 50% solubility for Co$_3$O$_4$. In addition, Ortega et al. (2014) found that intracellular concentrations of solubilized cobalt ions were similar for Co$_3$O$_4$ and cobalt chloride in human lung cells in vitro, suggesting that Co$_3$O$_4$ would release cobalt ions in vivo. Results with other biological fluids, such as serum and intestinal, alveolar, and interstitial fluids, indicate that the species of cobalt compound, parti-

### Physical and chemical properties of cobalt metal and some cobalt compounds

<table>
<thead>
<tr>
<th>Form$^a$</th>
<th>CAS No.</th>
<th>Formula</th>
<th>Molec. weight</th>
<th>Physical form</th>
<th>Density or specific gravity</th>
<th>Water solubility (g/100 cc)$^c$</th>
<th>Bioaccessibility (% solubility in gastric/lysosomal fluids)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cobalt metal</td>
<td>7440-48-4</td>
<td>Co$^0$</td>
<td>58.9$^b$</td>
<td>grey hexagonal or cubic metal$^f$</td>
<td>8.92$^c$</td>
<td>0.00029$^d$</td>
<td>100/100$^e$</td>
</tr>
<tr>
<td><strong>Water-soluble compounds</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acetate (org.)</td>
<td>71-48-7</td>
<td>Co(C$_2$H$_3$O$_2$)$_2$$^b$</td>
<td>249.1$^b$</td>
<td>red-violet, monocrystal$^c$</td>
<td>1.70$^b$</td>
<td>34.8$^a$</td>
<td>98/80$^d$</td>
</tr>
<tr>
<td>Chloride</td>
<td>7646-79-9</td>
<td>CoCl$_2$$^c$</td>
<td>129.8$^b$</td>
<td>blue hexagonal leaflets$^a$</td>
<td>3.36$^a$</td>
<td>45$^d$</td>
<td>100/100$^e$</td>
</tr>
<tr>
<td>Nitrate</td>
<td>10141-05-6</td>
<td>Co(NO$_3$)$_2$$^c$</td>
<td>182.9$^b$</td>
<td>red powder or crystals$^d$</td>
<td>2.49$^b$</td>
<td>67.0$^d$</td>
<td>96/100$^d$</td>
</tr>
<tr>
<td>Sulfate heptahydrate</td>
<td>10026-24-1</td>
<td>CoSO$_4$$^2$$\cdot$$\gamma$H$_2$O$^f$</td>
<td>281.1$^b$</td>
<td>red pink, monocrystal$^c$</td>
<td>1.95$^b$</td>
<td>60.4$^d$</td>
<td>100/100$^e$</td>
</tr>
<tr>
<td><strong>Poorly water-soluble compounds</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carbonate (org.)</td>
<td>513-79-1</td>
<td>CoCO$_3$$^d$</td>
<td>118.9$^d$</td>
<td>red, trigonal$^d$</td>
<td>4.13$^b$</td>
<td>0.00114$^d$</td>
<td>100/100$^e$</td>
</tr>
<tr>
<td>2-Ethylhexanoate (org.)</td>
<td>136-52-7</td>
<td>Co(C$<em>8$H$</em>{15}$O$_2$)$_2$</td>
<td>249.1$^b$</td>
<td>red-violet, monoclinic$^c$</td>
<td>1.70$^b$</td>
<td>34.8$^a$</td>
<td>98/80$^d$</td>
</tr>
<tr>
<td>Hydroxide</td>
<td>21041-93-0</td>
<td>Co(OH)$_2$</td>
<td>93.0$^b$</td>
<td>rose-red, rhomboic$^d$</td>
<td>3.60$^b$</td>
<td>0.00032$^d$</td>
<td>95/98$^e$</td>
</tr>
<tr>
<td>Naphthenate (org.)</td>
<td>61789-51-3</td>
<td>Co(C$_{11}$H$_7$O$_2$)$_2$</td>
<td>182.9$^b$</td>
<td>red powder or crystals$^d$</td>
<td>2.49$^b$</td>
<td>67.0$^d$</td>
<td>96/100$^d$</td>
</tr>
<tr>
<td>Oxalate (org.)</td>
<td>814-89-1</td>
<td>CoC$_2$O$_4$$^f$</td>
<td>147.0$^b$</td>
<td>white or reddish$^h$</td>
<td>3.02$^b$</td>
<td>0.0032$^d$</td>
<td>37/55$^d$</td>
</tr>
<tr>
<td>Oxide</td>
<td>1307-96-6</td>
<td>CoO$^a$</td>
<td>74.9$^f$</td>
<td>green-brown cubic$^c$</td>
<td>6.45$^d$</td>
<td>0.0004$^d$</td>
<td>100/92$^e$</td>
</tr>
<tr>
<td>(II,III) Oxide</td>
<td>1308-06-1</td>
<td>Co$_3$O$_4$$^f$</td>
<td>240.8$^b$</td>
<td>black, cubic$^d$</td>
<td>6.07$^d$</td>
<td>0.00016$^d$</td>
<td>2/2$^e$ (50%)$^e$</td>
</tr>
<tr>
<td>Propionate (org.)</td>
<td>1560-69-6</td>
<td>Co(C$_4$H$_9$O$_2$)$_2$</td>
<td>205.1$^f$</td>
<td>reddish solid$^d$</td>
<td>–</td>
<td>7.49$^d$</td>
<td>91/94$^h$</td>
</tr>
<tr>
<td>Stearate (org.)</td>
<td>1002-88-7</td>
<td>Co(C$<em>{17}$H$</em>{35}$O$_2$)$_2$</td>
<td>625.9$^c$</td>
<td>grey solid$^d$</td>
<td>–</td>
<td>0.007$^d$</td>
<td>14/16$^e$</td>
</tr>
<tr>
<td>Sulfide</td>
<td>1317-42-6</td>
<td>CoS$^l$</td>
<td>91.0$^b$</td>
<td>reddish octahedral$^d$</td>
<td>5.45$^b$</td>
<td>0.00038$^d$</td>
<td>1/1$^d$</td>
</tr>
</tbody>
</table>

$^a$Cobalt compounds selected for inclusion in the table are those with toxicological data or of commercial importance. All compounds contain Co(II) except where noted. Forms in italics have been tested for carcinogenicity or genetic toxicity or have mechanistic data; org. = organic compound; all others are inorganic.

$^b$Solubility data were converted to grams per 100 cubic centimeters as necessary.


$^d$Kreyling et al. 1990. Bioaccessibility was assessed by release of cobalt ions into culture medium in the presence of canine alveolar macrophages after two weeks of culture.
The solubility of cobalt compounds in water depends largely on pH, and cobalt is generally more mobile in acidic solutions than in alkaline solutions (IARC 1991, Paustenbach et al. 2013). Sulfates, nitrates, and chlorides of cobalt tend to be soluble in water, whereas oxides (including the mixed oxide, CoO₂), hydroxides, and sulfides tend to be poorly soluble or insoluble in water (Lison 2015). Organic cobalt compounds can be either soluble, as is cobalt(II) acetate, or insoluble, as are cobalt(II) carbonate and cobalt(II) oxalate (CDI 2006). In addition to low pH, solubilization of some poorly water-soluble compounds in biological fluids may be enhanced in the presence of binding proteins (IARC 2006).

### Chemical Characteristics

Cobalt (Co) is a naturally occurring transition element with magnetic properties. It is the 33rd most abundant element, making up approximately 0.0025% of the weight of Earth’s crust. Cobalt is a component of more than 70 naturally occurring minerals, including arsenides, sulfides, and oxides. The only stable and naturally occurring cobalt isotope is Co⁶⁰ (ATSDR 2004, WHO 2006). Metallic cobalt, Co(0), exists in two crystalline forms, hexagonal and cubic, which are stable at room temperature (IARC 1991; ATSDR 2004, WHO 2006). Cobalt predominantly occurs in two oxidation states, Co(II) and Co(III). Co(II) is much more stable than Co(III) in aqueous solution (Nilsen et al. 1985, Paustenbach et al. 2013) and is present in the environment and in most commercially available cobalt compounds (e.g., cobalt chloride, sulfide, and sulfate). Co(III) also is present in some commercially available cobalt compounds, including the mixed oxide (CoO₂) (IARC 1991, Paustenbach et al. 2013, Lison 2015) and some simple salts of Co(III) (e.g., Co₂O₄). Important salts of carboxylic acids include formate, acetate, citrate, naphthenate, linoleate, oleate, oxalate, resinate, stearate, succinate, sulfamate, and 2-ethylhexanoate.

### Use

Cobalt and cobalt compounds are used in numerous commercial, industrial, and military applications. On a global basis, the largest use of cobalt is in rechargeable battery electrodes (Shedd 2014b); however, U.S. production of rechargeable batteries has been very limited (Broid 2005). In 2012, the reported U.S. consumption of cobalt and cobalt compounds was approximately 8,420 metric tons, the majority used for superalloys (Shedd 2014b). Major uses for metallic cobalt include production of superalloys, cemented carbides, and bonded diamonds. Cobalt nanoparticles are used in medical applications (e.g., sensors, magnetic resonance imaging contrast enhancement, and drug delivery), and cobalt nanofibers and nanowires are used in industrial applications. Cobalt compounds are used as pigments for glass, ceramics, and enamels (oxides, sulfate, and nitrate), as driers for paints, varnishes, or lacquers (hydroxide, oxides, propionate, acetate, tallow, naphthenate, and 2-ethylhexanoate), as catalysts (hydroxide, oxides, carbonate, nitrate, acetate, oxalate, and sulfide), as adhesives and enamel frits (naphthenate, stearate, and oxides), and as trace mineral additives in animal diets (carbonate, sulfate, nitrate, oxides, and acetate). U.S. consumption of cobalt and cobalt compounds in 2012 is summarized in the following table.

The fastest-growing use for cobalt in recent years has been in high-capacity, rechargeable batteries, including nickel-cadmium, nickel-metal hydride, and lithium-ion batteries for electric vehicles and portable electronic devices such as smartphones and laptops (Maverick 2015). Many other uses for cobalt exist, including in integrated circuit contacts and semiconductor production. An emerging use is as a key element in several forms of “green” energy technology applications, including gas-to-liquids and coal-to-liquids processes, oil desulfurization, clean coal, solar panels, wind and gas turbines, and fuel cells, and in cobalt-based catalysts for sunlight-driven water-splitting to convert solar energy into electrical and chemical energy.

### Production

Cobalt metal is produced as a by-product from ores associated with copper, nickel, zinc, lead, and platinum-group metals and is most often chemically combined in its ores with sulfur and arsenic (Davis 2000, CDI 2006). The largest cobalt reserves are in the Congo (Kinshasa), Australia, Cuba, Zambia, Canada, Russia, and New Caledonia, with very limited production in the United States in recent years (Shedd 2014a). Except for a negligible amount of by-product cobalt produced from mining and refining of platinum-group metal ores, the United States did not refine cobalt in 2012 (Shedd 2014b). Cobalt has not been mined in the United States in over 30 years (ATSDR 2004); however, a primary cobalt mine, mill, and refinery were being established in Idaho in 2015 (Farquharson 2015). In 2012, 2,160 metric tons of cobalt was recycled from scrap. No cobalt has been sold from the National Defense Stockpile since 2009.

Metallic cobalt and several cobalt compounds are high-production-volume chemicals, based on their annual production or importation into the United States in quantities of at least 1 million pounds. Recent volumes of U.S. production, imports, and exports of cobalt metal and high-production-volume cobalt compounds are listed in the following table.

### Exposure

A significant number of people living in the United States are exposed to cobalt, based on several lines of evidence, including biological monitoring data demonstrating exposure in occupationally and non-occupationally exposed populations. Data from the U.S. Environmental Protection Agency’s Toxics Release Inventory (TRI) indi-
cate that production- and use-related releases of cobalt compounds have occurred at numerous industrial facilities in the United States.

In biomonitoring studies that measured cobalt in the urine of people exposed to cobalt from various sources, the highest levels generally were due to occupational exposures and failed hip implants; lower levels were due to exposure from normal implants or the environment. The lowest levels were observed in the general population (with unknown sources of exposure). The graph below shows the mean or median levels of urinary cobalt for the general population and for groups with known exposures. Data are reported for both U.S. and non-U.S. exposures; occupational and medical implant exposures outside the United States can be informative because of the similarity of production methods and implant compositions worldwide.

Urinary cobalt measurements in the U.S. general population have remained consistent since 1999, with geometric mean values between 0.316 and 0.379 µg/L, according to the National Health and Nutrition Examination Survey (NHANES) (CDC 2014). Urinary cobalt is considered a good indicator of absorbed cobalt (IARC 2006, WHO 2006), especially from recent exposures (ATSDR 2004). Levels of cobalt in blood (including whole blood, plasma, and serum) show a pattern similar to that for urinary cobalt levels.

### Occupational Exposure

The primary route of occupational exposure to cobalt is via inhalation of dust, fumes, mists, or gaseous cobalt carbonyl. Dermal contact with cemented carbide (i.e., hard-metal) powders and cobalt salts can result in systemic uptake. Occupational exposure to cobalt occurs in the following industries: (1) production of cobalt metal or salts, (2) metallurgical-related industries, (3) cemented carbides and bonded diamonds, (4) chemicals and pigments, and (5) electronics, “green” energy, and recycling. Occupational exposure has been documented by measurements of cobalt in ambient workplace air (as shown in the following table) and in blood, urine (as shown in the figure above), nails, and hair, and lung tissue from workers or deceased workers (IARC 1991, ATSDR 2004, IARC 2006, CDC 2013). The highest levels of cobalt in workplace air were generally for hard-metal manufacture involving cobalt metal powders (> 1,000 µg/m³ in some instances) (NTP 2009), production of cobalt salts, and metallurgical-related industries (> 10,000 µg/m³ in some instances) (IARC 2006). The highest cobalt levels in urine, blood, hair, and nails also were associated with exposure to cobalt powders.

### Surgical Implants

Total hip implants consist of (1) a femoral head attached to a stem that is inserted in the thigh bone (usually made of ceramic or metal) and (2) a socket or cup that is anchored in the pelvis (made of metal, ceramic, or polyethylene). Cobalt-chromium-molybdenum (CoCrMo) alloy is the predominant alloy used in metal-containing implants, such as metal-on-metal implants (in which both articulating surfaces are metal), polyethylene-on-metal implants, and metal-on-ceramic implants. Other metals, such as nickel, tungsten, iron, aluminum, and titanium, may also be used in implants. Knee implants may also contain cobalt metal; however, unlike some hip implants with metal-to-metal contact, knee implants are designed so that metal surfaces do not contact each other. Cobalt ions may be released into the body throughout the lifetime of a cobalt-containing device (Sampson and Hart 2012, Devlin et al. 2013). Urinary levels of cobalt identified from studies of hip implants reported as stable or that did not specifically address stability ranged from approximately 0.7 to 12 µg/L, compared with a range of 0.01 to 4.2 µg/L for the general population (as shown in the previous graph). Implants may fail because of excessive wear or corrosion by body fluids, increasing the levels of cobalt released from the implants (Sampson and Hart 2012). Dunstan et al. (2005) reported blood cobalt levels of 19 and 52 µg/L in two individuals with unstable (radiologically loose) metal-on-metal implants. In rare cases, high levels of cobalt from failed implants may be associated with toxicity. Recommended levels of blood cobalt for further clinical investigation and action were set at 7 µg/L in the United Kingdom (MHRA 2012) and 10 µg/L in the United States by the Mayo Clinic (2015).

### Environmental Exposure

The TRI reported that in 2013, on- and off-site industrial releases of cobalt and cobalt compounds totaled approximately 5.5 million pounds from 723 facilities in the United States (TRI 2014a). Calculations based on media-specific release data from the TRI indicate that releases to land accounted for 82% of total releases in 2013 (TRI 2014b,c). Worldwide, approximately 75,000 metric tons of cobalt enters the environment annually, with similar amounts coming from natural sources (40,000 metric tons) and sources related to human activities (35,000 metric tons) (Shedd 1993, CDI 2006). Recycling of electronic and electrical waste can result in release of cobalt to the environment; however, releases from this source are less of a concern in the United States than in other global regions where recycling is more common and less controlled (Julander et al. 2014).

The average concentration of cobalt in ambient air in the United States has been reported to be approximately 0.4 ng/m³ (ATSDR 2004). Levels can be orders of magnitude higher near source areas (e.g., near facilities processing cobalt-containing alloys and compounds) reported from outside the United States. The median cobalt concentration in U.S. drinking water has been reported to be less than 2.0 µg/L; however, levels as high as 107 µg/L have been reported.

For definitions of technical terms, see the [Glossary](#).
Cobalt bromide, formate, and sulfamate are designated as hazardous substances. Comprehensive Environmental Response, Compensation, and Liability Act

Emergency Planning and Community Right-To-Know Act

EPCRA Section 302: Threshold planning quantity (TPQ) = 100 lb for cobalt, (2,2′,11,12-tetraethyldizincinodimethylenebis(6-fluorophenolato))(2-) (also called fluoromeline) (solids in powder form with particle size < 100 µm or solution or molten form); = 10,000 lb for all other forms of fluoromeline; = 10 lb for cobalt carbonyl (solids in powder form with particle size < 100 µm or solution or molten form); = 10,000 lb for all other forms of cobalt carbonyl.

EPCRA Section 304: Reportable quantity (RQ) = 100 lb for fluoromeline; = 10 lb for cobalt carbonyl.

Toxics Release Inventory: Cobalt and cobalt compounds are listed substances subject to reporting requirements.

Federal Insecticide, Fungicide, and Rodenticide Act

Boiled linseed oil (containing no more than 0.33% manganese naphthenate and no more than 0.33% cobalt naphthenate) is exempt from the requirement of a tolerance when used as a coating agent for 5-ethyl hexahydro-1H,10H-carbazole-1-carboxylic acid. No more than 15% of the pesticide formulation may consist of boiled linseed oil, and this exemption is limited to use on rice before edible parts form.

Food and Drug Administration (FDA, an HHS agency)

Cobalt salts are prohibited from use in human food. All drugs containing cobalt (except radiotive forms of cobalt and its salts and cobalamins and its derivatives) have been withdrawn from the market because they were found to be unsafe or not effective, and they may not be compounded.

Chromium–cobalt–aluminum oxide used as a color additive for linear polyethylene surgical sutures used in general surgery must comprise no more than 2% by weight of the sutures material, not migrate to surrounding tissue, and conform to labeling requirements in 21 CFR 70.25.

Chromium cobalt–aluminum oxide may be used as a color additive in contact lenses in amounts not to exceed the minimum reasonably required to accomplish the intended coloring effect. Ferric ammonium ferrocyanide and ferric ferrocyanide used to color externally applied drugs (including those for use in the area of the eye) must not contain more than 200 ppm cobalt (as Co) and conform to labeling requirements in 21 CFR 70.25.

21 CFR 280.1 contains recommended drug labeling statements for over-the-counter cobalt preparations containing ≥ 0.5 mg cobalt as a cobalt salt per dosage unit and which require administration rates of ≥ 0.5 mg per dose and ≥ 2 mg per 24-hour period. An approved new drug application is required for marketing cobalt preparations intended for use by man.

21 CFR 872, 874, and 888 identify class designations (Class I, II, or III) of various cobalt-containing devices; = 0.0014 µg/m³; tap water = 6 µg/L.

Cobalt and cobalt compounds are listed substances subject to reporting requirements for shipment of cobalt-containing materials.

Cobalt compounds are listed as hazardous air pollutants (HAPs) for the following:

- Discharge limits for cobalt are imposed for wastewater discharges from centralized waste treatment facilities except discharges and activities exempted in 40 CFR 437.11(b), (c), and 40 CFR 421, Subpart AC.

Cobaltous bromide, formate, and sulfamate are designated as hazardous substances. Comprehensive Environmental Response, Compensation, and Liability Act

Emergency Planning and Community Right-To-Know Act

EPCRA Section 302: Threshold planning quantity (TPQ) = 100 lb for cobalt, (2,2′,11,12-tetraethyldizincinodimethylenebis(6-fluorophenolato))(2-) (also called fluoromeline) (solids in powder form with particle size < 100 µm or solution or molten form); = 10,000 lb for all other forms of fluoromeline; = 10 lb for cobalt carbonyl (solids in powder form with particle size < 100 µm or solution or molten form); = 10,000 lb for all other forms of cobalt carbonyl.

EPCRA Section 304: Reportable quantity (RQ) = 100 lb for fluoromeline; = 10 lb for cobalt carbonyl.

Toxics Release Inventory: Cobalt and cobalt compounds are listed substances subject to reporting requirements.

Federal Insecticide, Fungicide, and Rodenticide Act

Boiled linseed oil (containing no more than 0.33% manganese naphthenate and no more than 0.33% cobalt naphthenate) is exempt from the requirement of a tolerance when used as a coating agent for 5-ethyl hexahydro-1H,10H-carbazole-1-carboxylic acid. No more than 15% of the pesticide formulation may consist of boiled linseed oil, and this exemption is limited to use on rice before edible parts form.

Food and Drug Administration (FDA, an HHS agency)

Cobalt salts are prohibited from use in human food. All drugs containing cobalt (except radiotive forms of cobalt and its salts and cobalamins and its derivatives) have been withdrawn from the market because they were found to be unsafe or not effective, and they may not be compounded.

Chromium–cobalt–aluminum oxide used as a color additive for linear polyethylene surgical sutures used in general surgery must comprise no more than 2% by weight of the sutures material, not migrate to surrounding tissue, and conform to labeling requirements in 21 CFR 70.25.

Chromium cobalt–aluminum oxide may be used as a color additive in contact lenses in amounts not to exceed the minimum reasonably required to accomplish the intended coloring effect. Ferric ammonium ferrocyanide and ferric ferrocyanide used to color externally applied drugs (including those for use in the area of the eye) must not contain more than 200 ppm cobalt (as Co) and conform to labeling requirements in 21 CFR 70.25.

21 CFR 872, 874, and 888 identify class designations (Class I, II, or III) of various cobalt-containing devices; = 0.0014 µg/m³; tap water = 6 µg/L.

Cobalt and cobalt compounds are listed substances subject to reporting requirements for shipment of cobalt-containing materials.

Cobalt compounds are listed as hazardous air pollutants (HAPs) for the following:

- Discharge limits for cobalt are imposed for wastewater discharges from centralized waste treatment facilities except discharges and activities exempted in 40 CFR 437.11(b), (c), and 40 CFR 421, Subpart AC.

Cobaltous bromide, formate, and sulfamate are designated as hazardous substances. Comprehensive Environmental Response, Compensation, and Liability Act

Emergency Planning and Community Right-To-Know Act

EPCRA Section 302: Threshold planning quantity (TPQ) = 100 lb for cobalt, (2,2′,11,12-tetraethyldizincinodimethylenebis(6-fluorophenolato))(2-) (also called fluoromeline) (solids in powder form with particle size < 100 µm or solution or molten form); = 10,000 lb for all other forms of fluoromeline; = 10 lb for cobalt carbonyl (solids in powder form with particle size < 100 µm or solution or molten form); = 10,000 lb for all other forms of cobalt carbonyl.

EPCRA Section 304: Reportable quantity (RQ) = 100 lb for fluoromeline; = 10 lb for cobalt carbonyl.

Toxics Release Inventory: Cobalt and cobalt compounds are listed substances subject to reporting requirements.

Federal Insecticide, Fungicide, and Rodenticide Act

Boiled linseed oil (containing no more than 0.33% manganese naphthenate and no more than 0.33% cobalt naphthenate) is exempt from the requirement of a tolerance when used as a coating agent for 5-ethyl hexahydro-1H,10H-carbazole-1-carboxylic acid. No more than 15% of the pesticide formulation may consist of boiled linseed oil, and this exemption is limited to use on rice before edible parts form.

Food and Drug Administration (FDA, an HHS agency)

Cobalt salts are prohibited from use in human food. All drugs containing cobalt (except radiotive forms of cobalt and its salts and cobalamins and its derivatives) have been withdrawn from the market because they were found to be unsafe or not effective, and they may not be compounded.

Chromium–cobalt–aluminum oxide used as a color additive for linear polyethylene surgical sutures used in general surgery must comprise no more than 2% by weight of the sutures material, not migrate to surrounding tissue, and conform to labeling requirements in 21 CFR 70.25.

Chromium cobalt–aluminum oxide may be used as a color additive in contact lenses in amounts not to exceed the minimum reasonably required to accomplish the intended coloring effect. Ferric ammonium ferrocyanide and ferric ferrocyanide used to color externally applied drugs (including those for use in the area of the eye) must not contain more than 200 ppm cobalt (as Co) and conform to labeling requirements in 21 CFR 70.25.

21 CFR 872, 874, and 888 identify class designations (Class I, II, or III) of various cobalt-containing devices; = 0.0014 µg/m³; tap water = 6 µg/L.

Cobalt and cobalt compounds are listed substances subject to reporting requirements for shipment of cobalt-containing materials.

Cobalt compounds are listed as hazardous air pollutants (HAPs) for the following:

- Discharge limits for cobalt are imposed for wastewater discharges from centralized waste treatment facilities except discharges and activities exempted in 40 CFR 437.11(b), (c), and 40 CFR 421, Subpart AC.
Carcinogenicity

Cobalt–tungsten carbide powders and hard metals are reasonably anticipated to be human carcinogens based on limited evidence of carcinogenicity from studies in humans and supporting evidence from studies on mechanisms of carcinogenesis.

Cancer Studies in Humans

Epidemiological studies provide evidence for the carcinogenicity of cobalt–tungsten carbide powders and hard metals based on (1) consistent findings of excess lung-cancer mortality among cobalt–tungsten carbide hard-metal manufacturing workers across studies, (2) higher risks among individuals with higher exposure levels, and (3) positive exposure-response relationships that cannot be explained by confounding with tobacco smoking. However, the epidemiological data are limited, because there are few studies of independent populations.

The published epidemiological literature consists of mortality studies of two independent multi-plant cohorts of cobalt–tungsten carbide hard-metal manufacturing workers, one in France (Moulin et al. 1998) and one in Sweden (Hogstedt and Alexandersson 1990), and cohort studies of two individual factories included in the French multi-plant cohort (Lasfargues et al. 1994, Wild et al. 2000). The French multi-plant cohort included all 10 cobalt–tungsten carbide manufacturing plants in France; in addition, a nested case-control study of lung cancer was conducted within this cohort. The nested case-control study is most informative for evaluating cancer risk, because it used a semi-quantitative exposure scale to evaluate exposure-response relationships and considered potential confounding by exposure to tobacco smoking and other known or suspected occupational carcinogens. The cohort study of the largest French factory shares these limitations; however, because the workers were included in the multi-plant study, it does not provide independent evidence for carcinogenicity. In these two studies, four metrics of exposure were evaluated: (1) exposure level, which was the highest exposure score experienced during an individual’s work history (on a scale of 0 to 9), (2) duration of exposure at a level of 2 or higher, (3) unweighted cumulative dose, which assigned the same level to occasional and full-time exposure, thus favoring peak exposure, and (4) frequency-weighted cumulative dose, which weighted exposure level by the frequency of exposure, thus reducing the effect of occasional exposure. The Swedish study, although limited in size, provides supporting information for an independent population.

Excess lung-cancer mortality (of approximately 30%) was found in both multi-plant cohort studies (Hogstedt and Alexandersson 1990, Moulin et al. 1998); risk estimates were significantly higher among individuals with higher measures of exposure or longer time since first exposure (latency). In the nested case-control study (Moulin et
Lung cancer risk was significantly higher (odds ratio \(OR = 1.93, 95\% CI = 1.03 to 3.62, 35\) exposed cases) among workers exposed to cobalt–tungsten carbide (exposure level \(\geq 2\)) than among workers with little or no exposure (exposure level \(< 2\)). In exposure-response analyses using workers in the lowest exposure category as the comparison group, lung-cancer risk was significantly higher (by up to fourfold) for workers in the highest categories of both measures of cumulative dose, and an elevated risk of borderline statistical significance was found for workers in the highest exposure-level category. Positive exposure–response relationships were observed for all four measures of exposure: duration \(P_{\text{trend}} = 0.03\), unweighted cumulative dose \(P_{\text{trend}} = 0.01\), frequency–weighted cumulative dose \(P_{\text{trend}} = 0.08\), and exposure level \(P_{\text{trend}} = 0.08\). Adjustments for tobacco smoking or exposure to known or suspected carcinogens did not change the results. The Swedish study had limited ability to evaluate exposure–response relationships because of small numbers of exposed workers with lung cancer. Nevertheless, the risk of lung cancer mortality was significantly increased for workers with exposure duration of over 10 years and latency of over 20 years (standardized mortality ratio \(\text{SMR} = 2.78, 95\% CI = 1.11 to 5.72, 7\) exposed cases). Analyses restricted to workers with at least 10 years’ exposure or at least 20 years’ latency found somewhat higher SMRs for “high-exposed” than “low-exposed” workers (Hogstedt and Alexandersson 1990).

Excess risks of lung-cancer mortality were also found in studies of the two individual French factories. Wild et al. (2000) reported significantly elevated SMRs (by approximately twofold) for lung cancer among all male workers and among male workers ever employed in presintering workshops or with exposure levels of at least 2. The highest SMRs were observed for male workers in the highest exposure categories of all four exposure metrics (level, duration, and both measures of cumulative dose), although the trends were not statistically significant, and the risk estimates were imprecise. In the study by Lasfargues et al. (1994), the entire cohort had a significantly increased risk of lung cancer, and the risk was highest among workers in the highest exposure-level category. Although small, this study provides supporting evidence that the findings for the French industry-wide cohort were not due solely to the results for the large factory studied by Wild et al.

Both the French multi-plant cohort study (Moulin et al. 1988) and the larger study of an individual French factory (Wild et al. 2000) found higher risks of lung cancer for exposure to cobalt–tungsten carbide before sintering than after sintering (see Production). The authors stated that exposure was highest during presintering processes; however, there is no evidence of toxicological differences between presintered and sintered materials, and both materials release similar amounts of cobalt ions (see Studies on Mechanisms of Carcinogenesis).

It is unlikely that the excess risks of lung cancer found in the French studies were due to confounding by tobacco smoking or co-exposure to other known carcinogens. In the multi-plant study, the smoking-adjusted odds ratio for cobalt–tungsten carbide exposure \(OR = 2.6, 95\% CI = 1.16 to 5.82\) was similar to the unadjusted risk \(OR = 2.29, 95\% CI = 1.08 to 4.88\). Neither study found increased risks of smoking-related diseases, such as chronic bronchitis and emphysema, and adjustment for smoking or exposure to other occupational carcinogens did not change the findings in the exposure-response analyses (Moulin et al. 1988, Wild et al. 2000). Neither the Swedish multi-plant study (Hogstedt and Alexandersson 1990) nor the small French cohort study (Lasfargues et al. 1994) adjusted for smoking; however, surveys of smoking habits among a subset of workers found smoking rates similar to those in the general population. Overall, the studies are limited by the lack of quantitative exposure assessment and potential confounding; however, exposure misclassification would most likely reduce the likelihood of detecting a true effect.

### Studies on Mechanisms of Carcinogenesis

The findings from epidemiological studies are supported by studies on mechanisms of carcinogenesis. Although the mechanism(s) by which cobalt–tungsten carbide causes cancer have not been fully elucidated, it has been shown that (1) cobalt–tungsten carbide releases cobalt ions, (2) cobalt ions affect biochemical pathways related to carcinogenicity, (3) cobalt compounds are carcinogenic in experimental animals, (4) cobalt–tungsten carbide increases the production of reactive oxygen species (ROS) and causes greater cytotoxic, toxic, and genotoxic effects than does cobalt alone, (5) cobalt–tungsten carbide causes key events related to carcinogenesis, including genotoxicity, cytotoxicity, inflammation, and apoptosis (programmed cell death), and (6) the oxidative stress response resulting from increased ROS production may play a role in these key events and may also interfere with cells’ ability to repair damage caused by cobalt–tungsten carbide. The combination of the effects from cobalt ions and the oxidative stress response from ROS production provide plausible modes of action for the carcinogenicity of cobalt–tungsten carbide.

Studies in biological fluids, in vitro systems, experimental animals, and humans have demonstrated that cobalt is rapidly solubilized from cobalt–tungsten carbide. Cobalt dissolution rates were similar for presintered and sintered cobalt–tungsten carbide incubated in various artificial biological fluids (Stopford et al. 2003). Tungsten is not rapidly solubilized from cobalt–tungsten carbide, but can be phagocytized by macrophages (Lombaert et al. 2004). Cobalt was also released from hard-metal dust incubated with plasma and lung tissue (Edel et al. 1990). In experimental animals administered cobalt–tungsten carbide by intratracheal administration, cobalt was solubilized rapidly, cleared from the lung, distributed in the body, and excreted in the urine (Lison 1996). Rats exposed intratracheally to cobalt–tungsten carbide had more cobalt in the urine than did rats administered cobalt alone, suggesting that tungsten carbide increases the bioavailability of cobalt (Lasfargues et al. 1992). Several biomonitoring studies detected elevated levels of cobalt in the urine, lungs, and other tissues of workers exposed to cobalt–tungsten carbide hard metals (Rizzato et al. 1986, Nicolau et al. 1987, Gallorini et al. 1994, Sabbioni et al. 1994b, Scansetti et al. 1994, 1998, Linnainmaa and Kiilunen 1997, Goldoni et al. 2004).

Soluble cobalt compounds are genotoxic and carcinogenic in experimental animals. Cobalt and cobalt compounds that release cobalt ions in vivo are listed as reasonably anticipated to be human carcinogens in the Report on Carcinogens based on sufficient evidence of carcinogenicity from studies of cobalt metal, cobalt sulfate, cobalt chloride, and cobalt oxide in experimental animals and supporting evidence from studies on mechanisms of carcinogenesis. Cobalt ions produce ROS, which cause oxidative DNA damage and act on a number of cancer-related molecular targets. Cobalt ions disrupt cell-signaling pathways (Murata et al. 1999), inhibit DNA repair (Hartwig 2000, Hartwig et al. 2002), regulate genes involved in the response to hypoxia (Beyersmann 2002), replace or mimic essential divalent metal ions, thus altering cellular reactions (Nackerdien et al. 1991, Beyersmann and Hartwig 1992, Kawanishi et al. 1994, Lloyd et al. 1998), and interfere with mechanisms involved in cell-cycle control and modulation of apoptosis (DeBoeck et al. 2003b,c).

Numerous in vitro studies (reviewed in NTP 2009) and in vivo studies (Huaxa et al. 1995, Lasfargues et al. 1995) have shown greater cytotoxic effects (measured primarily by lactate dehydrogenase release) for cobalt–tungsten carbide than for either cobalt powder or tungsten carbide alone. The mixture’s greater in vitro toxicity to
Cobalt–tungsten carbide is genotoxic in vitro and causes mutations in the lungs of rats exposed in vivo. Its genotoxicity (clastogenic effects) may be caused by increased ROS production from the interaction between cobalt and tungsten carbide, from ionic cobalt, or from both. In addition, cobalt ions inhibit DNA repair, which may also contribute to cobalt–tungsten carbide’s genotoxic effects. Specifically, cobalt–tungsten carbide caused DNA strand breaks in mouse 3T3 fibroblasts and human peripheral-blood lymphocytes (Anard et al. 1997) and micronucleus formation in human peripheral-blood lymphocytes (Van Goethem et al. 1997, De Boeck et al. 2003c). In these studies, cobalt–tungsten carbide was more genotoxic than cobalt alone. In rats exposed by intratracheal instillation, cobalt–tungsten carbide caused DNA damage and micronucleus formation in the lung (type II pneumocytes) (De Boeck et al. 2003a). No increase in DNA damage or micronucleus formation was observed in rat peripheral-blood lymphocytes; however, it is unclear whether circulating lymphocytes are a good reporter for monitoring genotoxic effects from inhaled particles. In humans, neither DNA damage nor micronucleus formation was increased in lymphocytes of cobalt–tungsten carbide hard-metal workers, compared with unexposed workers; however, this study was limited by small sample size (De Boeck et al. 2000). Multiple regression analyses (Mateuca et al. 2005) indicated that both end points were associated with an interaction between tobacco smoking and exposure, and that micronucleus formation was associated with smoking, working in a cobalt–tungsten carbide plant, and having variant forms of genes coding for DNA repair enzymes (X-ray repair cross-complementing group 3 and 8-oxoguanine DNA glycosylase).

In addition, although the pathogenesis of hard-metal disease is not fully understood, it may involve differences in the susceptibility (genetic and/or health-related) of affected individuals to the toxic effects of increased ROS production due to cobalt–tungsten carbide exposure. Further, the mechanisms for fibrosing alveolitis and lung cancer in hard-metal workers may be related, conceivably involving oxidative damage and/or inflammatory events (IARC 2006).

Cancer Studies in Experimental Animals

No studies in experimental animals were identified that evaluated the relationship between cancer and exposure specifically to cobalt–tungsten carbide powders or hard metals.

Properties

This listing includes powders and dusts (either unsintered or sintered) containing both cobalt and tungsten carbide and hard metals containing both cobalt and tungsten carbide. Powders containing both cobalt and tungsten carbide may result from combination of these materials during manufacture of hard metals, and dusts containing both materials may result from production, finishing, or maintenance (e.g., sharpening or grinding) of cobalt–tungsten carbide hard-metal products. Cobalt–tungsten carbide hard metals are composites of tungsten carbide particles (either alone or in combination with smaller amounts of other carbides) with a metallic cobalt powder as a binder, pressed into a compact, solid form at high temperatures by a process known as “sintering.” Cobalt–tungsten carbide hard metals are commonly referred to as “cemented carbides” in the United States, but the term “sintered carbide” also may be used, and some sources refer to cobalt–tungsten carbide products simply as “tungsten carbides” (Brookes 2002).

The physical properties of cobalt–tungsten carbide hard metals vary with the relative proportions of cobalt, tungsten carbide, and other carbides, but they have common properties of extreme hardness, abrasion resistance, and toughness. Tungsten carbide is hard (able
to resist cutting, abrasion, penetration, bending, and stretching) but brittle; cobalt is soft but tough (able to withstand great strain without tearing or breaking). The composition of commercial-grade cobalt–tungsten carbide hard metals can vary greatly; it generally ranges from 50% to 97% tungsten carbide (along with other metallic carbides such as titanium carbide or tantalum carbide) and from 3% to 16% cobalt, with variations in grain size and additives. The proportion of cobalt as the binding metal in the composite hard metal depends on the intended use (Azom 2002). Cobalt–tungsten carbide hard metals for various uses have Vickers hardness values (a measure of the resistance of a substance to indentation by a diamond penetrator of special profile) typically ranging from 1250 to 1900 (Brookes 1998).

The crystalline structure of cobalt–tungsten carbide includes the structures individually of cobalt, which can exist as either hexagonal or cubic crystals, and tungsten carbide, which consists primarily of W, C, WC, and possibly other carbides (Upadhyaya 1999b). The phase diagram for the combination of cobalt and tungsten carbide is extremely complex, as tungsten can form a solid solution in cobalt, and cobalt can form carbides with carbon; the overall relationship varies with the concentrations of the major components and the temperature.

Mixtures of cobalt and tungsten carbide are more active than the individual components in adsorption of water vapor (with respect to both the amount adsorbed and the interaction energy) and in the catalytic decomposition of hydrogen peroxide (Zanetti and Fubini 1997). Physical and chemical properties of tungsten carbide and cobalt are listed in the following table.

<table>
<thead>
<tr>
<th>Property</th>
<th>Cobalt</th>
<th>Tungsten carbide</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular or atomic weight</td>
<td>58.9</td>
<td>195.9</td>
</tr>
<tr>
<td>Density</td>
<td>8.92</td>
<td>15.6</td>
</tr>
<tr>
<td>Melting point</td>
<td>1,495°C</td>
<td>2,785°C</td>
</tr>
<tr>
<td>Boiling point</td>
<td>2,927°C</td>
<td>6,000°C</td>
</tr>
<tr>
<td>Vapor pressure</td>
<td>1 Pa at 1,517°C (0.0075 mmHg)</td>
<td>NR</td>
</tr>
</tbody>
</table>

Source: HSDB 2010. NR = not reported.

**Use**

About 70% of cobalt–tungsten carbide hard-metal production is used for cutting tools and 30% for wear-resistant materials, primarily for tools for mining and grinding operations (Santhanam 2003). Hard-metal grades for machining are assigned International Organization for Standardization (ISO) codes beginning with "P" for machining of steel, "M" for multiple purposes, including machining of steel, nickel-based superalloys, and higher-tensile-strength (ductile) cast iron, and "K" for cutting of lower-tensile strength (gray) cast iron, nonferrous metals, and nonmetallic materials.

**Production**

Cobalt–tungsten carbide hard metals were developed in Germany during and after World War I and marketed commercially by a German company in 1927 as Widia, which consisted of tungsten carbide with 6% cobalt as binder (Brookes 1998, Upadhyaya 1998a). Cobalt–tungsten carbide hard-metal manufacturing processes vary somewhat, but all involve production of cobalt and tungsten carbide powders, which are mixed, pressed into a compact, solid form, and sintered by heating to about 1,500°C. The manufacturing process consists of three steps: Step 1, producing the cobalt and tungsten carbide powders; Step 2, mixing, drying, pressing, presintering, shaping the presintered hard metal, and sintering; and Step 3, finishing the sintered products, which includes grinding and sharpening.

Worldwide use of cemented carbides has increased steadily over the years, from about 10 tons in 1930 to 30,000 tons per year in the early 2000s (Azom 2002). In 2004, estimated U.S. production of hard-metal products totaled 5,527 metric tons (6,080 tons) (Hsu 2004). The U.S. Geological Survey (USGS 2008a,b) estimated that 792 metric tons (873 tons) of cobalt (9.3% of total U.S. cobalt consumption) and 6,610 metric tons (7,286 tons) of tungsten (56% of total U.S. tungsten consumption) was used in the production of cemented carbides in the United States in 2007. In 2008, 127 U.S. and Canadian companies were identified that produced or supplied cobalt–tungsten carbide and materials made from cobalt–tungsten carbide (Thomas-Net 2008), and the Cemented Carbide Producers Association had 22 U.S. members and partner members (CCPA 2008). In 2007, the United States imported about 1.6 million kilograms (1,800 tons) and exported about 1.3 million kilograms (1,400 tons) of tungsten carbide (USITC 2008); no data specific to U.S. imports or exports of cobalt–tungsten carbide were found.

**Exposure**

The major source of exposure to cobalt–tungsten carbide powders and hard metals is occupational. However, people who live in the vicinity of hard-metal production or maintenance facilities could be exposed to cobalt–tungsten carbide hard-metal dusts. Although no exposure levels for the general population were found, some studies provided data on possible environmental contamination from the manufacture or maintenance of hard-metal products. Soil samples from the rear of a cemented carbide tool-grinding plant contained cobalt at concentrations of up to 12,780 mg/kg (Abraham and Hunt 1995). The concentrations of tungsten and cobalt in airborne particulates in Fallon, Nevada, and four nearby towns were characterized by Sheppard et al. (2006), who found higher levels of tungsten (0.1 to 40.9 ng/m³) and cobalt (0.02 to 0.16 ng/m³) in Fallon than in the other towns. The authors suggested that a hard-metal facility located in Fallon could be a candidate source for airborne exposure to the metals, a suggestion that has been disputed (see NTP 2009).

Sources of occupational exposure to cobalt–tungsten carbide during the manufacture of hard metals include the processes of mixing, drying, pressing, presintering, shaping, and sintering (parts of Step 2, as described under Production) and the processes of grading and sharpening sintered products (parts of Step 3, as described under Production). Exposure to cobalt–tungsten carbide hard metals can also occur from other miscellaneous manufacturing operations, during processing of hard-metal scrap for recycling, and during end use and maintenance of hard-metal tools. Particle size (and hence respirable fraction), morphology, and concentrations of airborne dusts and bulk dusts were found to differ among production areas (Stefaniak et al. 2007). For cobalt-containing particles, the minimum mass median aerodynamic diameter (MMAD) was 6 μm (for dry grinding), and the maximum MMAD was over 18 μm (for scrap reclamation and pressing operations); the MMAD for powder mixing was around 10 μm, which is generally considered the maximum diameter for respirable particles in humans. Inhalable, thoracic, and respirable particles were found in all work areas of three facilities that together carried out the cobalt–tungsten carbide manufacturing process, with the highest levels reported for the powder-mixing area (Stefaniak et al. 2009). Cobalt and tungsten have been detected in workers’ urine, blood, hair, toenails, and bronchoalveolar lavage fluid, and through open lung and transbronchial biopsy (NTP 2009).

Step 2 processes, particularly powder-processing operations, generally are associated with the highest airborne exposures; several studies reported cobalt concentrations approaching or exceeding 5,000 μg/m³ (NTP 2009). A maximum mean cobalt air concentration of 32,740 μg/m³ (range = 44 to 438,000 μg/m³) was reported during weighing and mixing operations in a U.S. manufacturing facility.

For definitions of technical terms, see the Glossary.
et al. (1984). An Italian study reported a mean tungsten air concentration of 26 μg/m³ (Sabbioni et al. 1994a), and a German study reported a maximum single measurement of 254 μg/m³ (Kraus et al. 2001). Among workers involved in Step 2 manufacturing processes, cobalt was detected in the urine (at up to 2,100 μg/L), blood or serum (at up to 32 μg/L), and hair (at up to 25.8 ppm), and tungsten was detected in urine (at up to 169 μg/L).

Cobalt air concentrations reported for Step 3 processes (including tool finishing, grinding, and reconditioning operations) have generally been lower than those for Step 2, but have exceeded 1,000 μg/m³ in some studies (NTP 2009). For Step 3 processes, a maximum mean cobalt air concentration of 1.292 μg/m³ and a maximum single measurement of 2.440 μg/m³ were reported, both for dry-grinding operations. For tungsten in air, a maximum mean concentration of 5,160 μg/m³ and a maximum single measurement of 12,800 μg/m³ were reported. Among workers involved specifically in Step 3 processes, cobalt was detected in urine (at up to 730 μg/L), blood (at up to 39 μg/L), and hair (at up to 9.11 ppm). Tungsten also was detected in urine (at up to 1,000 μg/L) and blood (at up to 60 μg/L).

A few studies reported on exposure for jobs outside of the cobalt–tungsten carbide production process. Mc Dermott (1971) reported airborne cobalt concentrations during packing operations (10 to 250 μg/m³), equipment cleaning (40 to 820 μg/m³), and miscellaneous operations (10 to 6,700 μg/m³), but the nature of these operations was not defined further. Maintenance activities (including housekeeping) were reported by Scansetti et al. (1985) to result in airborne cobalt concentrations exceeding 50 μg/m³, and Kraus et al. (2001) reported urinary levels associated with maintenance activities ranging from 1.3 to 4.7 μg/L for cobalt and 1.5 to 5.3 μg/L for tungsten.

Information on exposure from the end use of hard-metal tools is limited; however, exposure appears to be minimal. Pellet et al. (1984) reported cobalt air concentrations of 180 to 193 μg/m³ and a mean urinary cobalt concentration of 11.7 μg/L associated with use of hard metal; however, no additional information was provided for these data. No other information was found that directly demonstrated exposure to cobalt–tungsten carbide powders and hard metals by end users of products containing the material. The Washington State Department of Labor, in a Hazard Alert issued in March 1995, stated that there was no evidence of substantial exposure to cobalt during the use of tools containing tungsten carbide or other hard metals (WSDLI 1995).

Several studies found significant correlations between cobalt concentrations in air and in workers’ blood or urine (Ichikawa et al. 1985, Scansetti et al. 1985, Lison et al. 1994, Sabbioni et al. 1994b). Urinary cobalt levels for hard-metal workers have been reported to increase through the workday (Torra et al. 2005) and workweek (Lison et al. 1994, Scansetti et al. 1998, Torra et al. 2005). In one study, urinary cobalt concentrations were significantly higher (P < 0.005) at the end of a shift than at the beginning of the shift, with significant increases “day in and day out” during the workweek (Torra et al. 2005).

**Regulations**

**U.S. Environmental Protection Agency (EPA)**

**Clean Water Act**

Cobalt and cobalt discharge limits are imposed for numerous processes during the production of tungsten or cobalt at secondary tungsten and cobalt facilities processing tungsten or tungsten carbide scrap raw materials.

Discharge limits for tungsten are imposed for numerous processes during the production of tungsten at primary tungsten facilities.

Discharge limits for cobalt are imposed for numerous processes during the production of cobalt at primary cobalt facilities.
For definitions of technical terms, see the Glossary.